SHREE GANESH REMEDIES
|
SHREE GANESH REMEDIES Last 5 Year Financial Ratios History
[Standalone]
| Mar2024 | Mar2023 | Mar2022 | Mar2021 | Mar2020 | |
|---|---|---|---|---|---|
| Operational & Financial Ratios | |||||
| Earnings Per Share (Rs) | 21.89 | 12.14 | 11.16 | 9.75 | 10.73 |
| CEPS(Rs) | 26.65 | 15.13 | 13.84 | 10.32 | 9.81 |
| DPS(Rs) | - | 0.50 | 0.50 | 1.75 | 1.50 |
| Book NAV/Share(Rs) | 95.07 | 69.70 | 51.28 | 49.97 | 46.92 |
| Tax Rate(%) | 26.34 | 24.97 | 25.58 | 24.68 | 24.48 |
| Margin Ratios | |||||
| Core EBITDA Margin(%) | 32.33 | 25.38 | 25.14 | 27.81 | 18.74 |
| EBIT Margin(%) | 29.97 | 22.10 | 25.46 | 26.52 | 22.05 |
| Pre Tax Margin(%) | 29.51 | 21.91 | 25.26 | 26.38 | 21.81 |
| PAT Margin (%) | 21.74 | 16.44 | 18.80 | 19.87 | 16.47 |
| Cash Profit Margin (%) | 26.46 | 20.49 | 23.48 | 25.43 | 20.31 |
| Performance Ratios | |||||
| ROA(%) | 17.51 | 13.81 | 19.47 | 17.29 | 20.56 |
| ROE(%) | 26.87 | 20.41 | 24.02 | 21.18 | 25.35 |
| ROCE(%) | 27.83 | 22.46 | 32.47 | 27.51 | 32.63 |
| Asset Turnover(x) | 0.81 | 0.84 | 1.04 | 0.87 | 1.25 |
| Sales/Fixed Asset(x) | 1.42 | 1.56 | 1.97 | 1.77 | 2.53 |
| Working Capital/Sales(x) | 2.51 | 2.25 | 2.39 | 1.77 | 2.32 |
| Efficiency Ratios | |||||
| Fixed Capital/Sales(x) | 0.70 | 0.64 | 0.51 | 0.56 | 0.40 |
| Receivable days | 68.40 | 91.91 | 81.17 | 111.39 | 82.32 |
| Inventory Days | 60.91 | 62.85 | 67.47 | 67.74 | 37.53 |
| Payable days | 75.08 | 96.47 | 77.29 | 83.44 | 39.76 |
| Valuation Parameters | |||||
| PER(x) | 30.48 | 20.56 | 26.39 | 28.43 | 5.01 |
| PCE(x) | 25.04 | 16.50 | 21.28 | 26.86 | 5.48 |
| Price/Book(x) | 7.02 | 3.58 | 5.78 | 6.70 | 1.55 |
| Yield(%) | - | 0.20 | 0.17 | 0.52 | 2.07 |
| EV/Net Sales(x) | 6.97 | 3.65 | 4.94 | 6.76 | 1.12 |
| EV/Core EBITDA(x) | 19.55 | 13.81 | 16.39 | 21.08 | 4.34 |
| EV/EBIT(x) | 22.63 | 16.34 | 19.41 | 25.50 | 5.09 |
| EV/CE(x) | 5.54 | 2.78 | 5.72 | 5.48 | 1.26 |
| M Cap / Sales | 6.81 | 3.42 | 5.00 | 6.83 | 1.11 |
| Growth Ratio | |||||
| Net Sales Growth(%) | 37.81 | 28.15 | 45.26 | -16.00 | 65.44 |
| Core EBITDA Growth(%) | 85.76 | 12.43 | 36.50 | 4.08 | 52.65 |
| EBIT Growth(%) | 89.87 | 12.49 | 39.44 | 1.03 | 45.25 |
| PAT Growth(%) | 85.17 | 13.33 | 37.36 | 1.35 | 54.36 |
| EPS Growth(%) | 80.38 | 8.76 | 14.48 | -9.14 | 54.36 |
| Financial Stability Ratios | |||||
| Total Debt/Equity(x) | 0.30 | 0.38 | - | - | 0.05 |
| Current Ratio(x) | 2.98 | 2.63 | 2.99 | 3.73 | 3.60 |
| Quick Ratio(x) | 2.02 | 1.91 | 2.08 | 2.48 | 3.03 |
| Interest Cover(x) | 64.88 | 113.31 | 124.49 | 192.28 | 91.53 |
| Total Debt/Mcap(x) | 0.04 | 0.10 | - | - | 0.04 |
Compare Financial Ratios of peers of SHREE GANESH REMEDIES
| Peers & Returns | Market Capitalization | 1 Week | 1 Month | 1 Year | ||
| SHREE GANESH REMEDIES | ₹879.0 Cr | -5.1% | 2.4% | 1% | Stock Analytics | |
| SUN PHARMACEUTICAL INDUSTRIES | ₹433,920.0 Cr | -0.1% | 1.7% | 45.7% | Stock Analytics | |
| DIVIS LABORATORIES | ₹155,160.0 Cr | -0.1% | -2.2% | 56.9% | Stock Analytics | |
| CIPLA | ₹118,917.0 Cr | 1.7% | 0.5% | 23.7% | Stock Analytics | |
| DR REDDYS LABORATORIES | ₹112,017.0 Cr | 5.7% | 12.4% | 18.5% | Stock Analytics | |
| ZYDUS LIFESCIENCES | ₹97,997.1 Cr | -1.4% | 3.1% | 44.8% | Stock Analytics | |
SHREE GANESH REMEDIES Share Price vs Sensex
| Share Price Returns(%) | 1 Week | 1 Month | 1 Year |
| SHREE GANESH REMEDIES | -5.1% |
2.4% |
1% |
| SENSEX | -5% |
0.6% |
9.2% |
You may also like the below Video Courses
